FGFR2 fusion

News alerts, weekly reports and conference planners

Entrez ID:

2263

Related biomarkers:

‹

›

Related tests:

FoundationOne® CDx (110)

FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1
FGFR2 fusion	Biliary Tract Cancer	FGFR2 fusion	Biliary Tract Cancer	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	FGFR inhibitor Sensitive: A2 - Guideline FGFR inhibitor Sensitive : A2	FGFR inhibitor Sensitive: A2 - Guideline FGFR inhibitor Sensitive : A2
FGFR2 fusion	Urothelial Cancer	FGFR2 fusion	Urothelial Cancer	erdafitinib Sensitive: B - Late Trials erdafitinib Sensitive : B	erdafitinib Sensitive: B - Late Trials erdafitinib Sensitive : B
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	KIN-3248 Sensitive: B - Late Trials KIN-3248 Sensitive : B	KIN-3248 Sensitive: B - Late Trials KIN-3248 Sensitive : B
FGFR2 fusion	Solid Tumor	FGFR2 fusion	Solid Tumor	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1
FGFR2 fusion	Glioma	FGFR2 fusion	Glioma	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1
FGFR2 fusion	Gastric Cancer	FGFR2 fusion	Gastric Cancer	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1
FGFR2 fusion	Breast Cancer	FGFR2 fusion	Breast Cancer	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1
FGFR2 fusion	Hepatocellular Cancer	FGFR2 fusion	Hepatocellular Cancer	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2
FGFR2 fusion	Gastric Cancer	FGFR2 fusion	Gastric Cancer	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2
FGFR2 fusion	Gastrointestinal Cancer	FGFR2 fusion	Gastrointestinal Cancer	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	ICP-192 Sensitive: C2 – Inclusion Criteria ICP-192 Sensitive : C2	ICP-192 Sensitive: C2 – Inclusion Criteria ICP-192 Sensitive : C2
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	RLY-4008 Sensitive: C2 – Inclusion Criteria RLY-4008 Sensitive : C2	RLY-4008 Sensitive: C2 – Inclusion Criteria RLY-4008 Sensitive : C2
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	TT-00420 Sensitive: C2 – Inclusion Criteria TT-00420 Sensitive : C2	TT-00420 Sensitive: C2 – Inclusion Criteria TT-00420 Sensitive : C2
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	HMPL-453 Sensitive: C2 – Inclusion Criteria HMPL-453 Sensitive : C2	HMPL-453 Sensitive: C2 – Inclusion Criteria HMPL-453 Sensitive : C2
FGFR2 fusion	Solid Tumor	FGFR2 fusion	Solid Tumor	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR2 fusion	Colon Cancer	FGFR2 fusion	Colon Cancer	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR2 fusion	Solid Tumor	FGFR2 fusion	Solid Tumor	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR2 fusion	Pancreatic Cancer	FGFR2 fusion	Pancreatic Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3

FGFR2 fusion

Associations